In a pioneering collaboration, Accelagen is joining forces with Griffith University to support a world-first Phase I clinical trial that could revolutionise the treatment of spinal cord injuries (SCI). This groundbreaking study, which focuses on a novel cell-based therapy, aims to restore lost functions in patients with severe spinal cord damage and offers hope for those affected by one of the most debilitating conditions worldwide.
The study explores the potential of olfactory ensheathing cells (OECs)—a type of nervous system supporting cell within the nose that has been shown to have nerve repair properties. By extracting these cells from a patient, purifying and expanding them, and then reintroducing them to a spinal cord injury site, researchers hope to bridge damaged nerve tissues and promote nerve regeneration. The ultimate goal is to stimulate renewed function for SCI patients to enable more feeling, mobility and the potential to even improve functional movement; a result that could transform lives.
A Unique Partnership to Bring Innovation to the Clinic
The role of Accelagen in this innovative study goes beyond providing clinical trial services. With its extensive expertise in running early-phase studies, particularly in the fields of neurology and cell therapies, Accelagen is positioned as a crucial partner to aid in the success of the trial. Our responsibilities will include providing upfront protocol advice, overseeing the study, managing clinical data, providing regulatory support, and ensuring that the trial’s findings can progress through the necessary regulatory pathways. Our team will also provide essential services such as data management, biostatistics, and writing the clinical study report. This groundbreaking study has complexities not always experienced in clinical trials, including the collection, processing and re-implantation of cells from patients, and Accelagen will work with Griffith University to ensure that all ethics, logistics and regulatory requirements are met to make this trial as smooth and successful as possible.
The Breakthrough Research by Professor James St John at Griffith University
Initiating a human clinical trial like this is only possible after many years of discovery research, which has been meticulously conducted by Professor James St John and his team at Griffith University. Professor St John explains, “Our innovative nerve bridges, combined with high purity olfactory cells, offer what we think is the best hope for treating spinal cord injury.”
The research team has performed extensive preclinical testing of this complex therapy, showing positive effects of OEC transplantation, and is now excited to apply this therapy to help clinical patients with limited treatment options.
Moving from the research phase into patient trials is a complex process, and this is where Accelagen’s experience and knowledge will be critical. Accelagen is proud to be partnering with Professor St John and Griffith University to conduct this high impact trial.
A Game-Changing Approach to Spinal Cord Injury
At present, spinal cord injury is an area where medical advancements have been limited, with most treatments focusing on supportive care rather than restorative therapies. The potential of using OECs as a cell therapy is a game-changer, as this approach could offer a way to repair nerve damage; not just manage symptoms.
This clinical trial is just the beginning. If successful, the therapy could expand to treat other types of nerve damage, offering hope for individuals with conditions like multiple sclerosis, neurodegenerative diseases, or even traumatic brain injury.
The Path Forward: More Trials, More Innovations
Accelagen’s team brings valuable experience from similar trials utilising cell-based therapies. This makes Accelagen an ideal partner for the Griffith University team. The company’s deep knowledge of clinical trial logistics, such as how to handle the transportation of live cells and the complexities of patient visits, will ensure the success of this study.
One of the unique challenges of this trial is the use of autologous cell therapy (cells taken from the patient, processed, and returned to the body). This process requires meticulous care to ensure the cells remain viable and are reintroduced in a way that maximises their therapeutic potential. Our regulatory team has been working with the university researchers to establish appropriate quality criteria that ensure the quality of the cells meets the strict criteria for implantation. The clinical trial also includes long term, intensive post-surgery physical rehabilitation, to reinforce nerve regeneration and recovery.
Why This Partnership Matters for Australia
What makes this collaboration particularly exciting is that it highlights the growing capability of Australian universities and companies to lead the way in cutting-edge biomedical research and development. By supporting local research and commercialising innovative therapies within Australia, this trial sets a global example of how universities, industry, foundations and government can work together to bring breakthrough treatments to patients.
Not only does this project promise to help people with spinal cord injuries, but it also highlights the importance of creating a robust ecosystem for medical innovation in Australia. Accelagen’s approach, acting as both a partner and a strategic advisor, helps ensure that these groundbreaking therapies reach patients as quickly and safely as possible.
A Bright Future for SCI Treatment
As Accelagen and Griffith University move forward with this world-first clinical trial, the future of spinal cord injury treatment looks brighter than ever. If successful, this trial could be a pivotal moment in the field of regenerative medicine, offering hope to patients who currently face a life of limited independence and freedoms.
With further trials and continued collaboration between universities, research institutions, and companies like Accelagen, Australia is positioned to remain at the forefront of medical innovation. The team’s commitment to partnering with local researchers, fostering new ideas, and navigating the complex clinical development process is what will ultimately help these groundbreaking therapies reach the people who need them most.
For those interested in learning more about this clinical trial, please contact Griffith University directly for further information. For researchers or institutions with their own innovative ideas looking to move their therapies forward, Accelagen is always open to discussions on how it can help bring new therapies from the lab to the clinic.
—
About Accelagen:
Accelagen is an Australian-based company specialising in regulatory affairs, clinical research and product development services. With a strong focus on early-phase studies and cell therapy trials, Accelagen works with researchers and organisations to bring innovative therapies to market. Through their deep expertise in clinical trial management, regulatory affairs, and data analysis, Accelagen plays a critical role in helping local researchers navigate the complex journey from the lab to the clinic.
Contact Information: For more information about the spinal cord injury clinical trial please contact Griffith University at [email protected]. To enquire about Accelagen’s services and how we can support your clinical development needs, please visit our website.